S83551 |
ML355 |
源叶(MedMol) | 98% |
- 提示:详情请下载说明书。
- 产品描述: ML355是有效的选择性h12-LOX抑制剂,IC50为290 nM
- 靶点: 12-LOX;Lipoxygenase
- 体外研究:
ML355 displays nM potency against 12-LOX and excellent selectivity over related lipoxygenases and cyclooxygenases
- 体内研究:
In vivo PK studies where ML355 is administered as a solution via IV (3mpk) and PO (30mpk) demonstrated that ML355 is orally bioavailable (%F = 20) with good half-life (T1/2 = 2.9 hours). At 30 mpk dosing, ML355 achieves a Cmax of over 135 times the in vitro IC50 and remains over IC50 value for over 12 hours. The compound has low clearance (3.4 mL/min/kg) and good overall exposure (AUCinf) of 38 µM. Although, the volume of distribution (VD) observed is low (0.55 L/kg), the rest of the PK profiling results suggest a reasonable distribution between tissue and blood
- 细胞实验: Cell lines: U87 cells Concentrations: 10 µM Incubation Time: 24 h Method: Cells were treated with indicated concentration of drug for 24 h.
- 动物实验: Animal Models: C57BL/6 mice Dosages: 15 or 30 mg/kg Administration: p.o.
- 参考文献:
1. Luci D, et al. Discovery of ML355, a Potent and Selective Inhibitor of Human 12-Lipoxygenase. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-2013 Apr 12 [updated 2014 Sep 18]. 2. Yang X, et al. miR-18a promotes glioblastoma development by down-regulating ALOXE3-mediated ferroptotic and anti-migration activities. Oncogenesis. 2021 Feb 12;10(2):15. 3. Adili R, et al. First Selective 12-LOX Inhibitor, ML355, Impairs Thrombus Formation and Vessel Occlusion In Vivo With Minimal Effects on Hemostasis. Arterioscler Thromb Vasc Biol. 2017 Oct;37(10):1828-1839.
- 溶解性: Soluble in DMSO
- 保存条件: -20℃
- 配置溶液浓度参考:
1mg 5mg 10mg 1 mM 2.265 ml 11.324 ml 22.649 ml 5 mM 0.453 ml 2.265 ml 4.53 ml 10 mM 0.226 ml 1.132 ml 2.265 ml 50 mM 0.045 ml 0.226 ml 0.453 ml
- 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)